Table 2.
Phenotypic characterisics of mecC-MRSA.
| ID | CC | agr | CS | Haemolysis on SBA | BF | agr acitivity level (predicted) | |
|---|---|---|---|---|---|---|---|
| CAMP | SPDH | ||||||
| IMT31818 | 599 | I | − | − | None | 0 | 0 |
| IMT32509 | 599 | I | + | + | α, β, δ | 0 | ++ |
| IMT32513 | 599 | I | + | + | α, β, δ | 0 | ++ |
| IMT36943 | 599 | I | + | + | α, β, δ | 0 | ++ |
| IMT36947 | 599 | I | + | + | α, β, δ | 1 | ++ |
| IMT36948 | 599 | I | + | + | α, β, δ | 1 | ++ |
| IMT38116 | 599 | I | + | + | α, β, δ | 0 | ++ |
| IMT39824 | 599 | I | − | − | None | 0 | 0 |
| IMT39825 | 599 | I | + | + | α, β, δ | 0 | ++ |
| RKI5962 | 599 | I | + | + | α, β, δ | 0 | ++ |
| RKI5963 | 599 | I | + | + | α, β, δ | 0 | ++ |
| RKI5964 | 599 | I | + | + | α, β, δ | 0 | ++ |
| IMT36945 | 49 | II | − | − | None | 0 | 0 |
| RKI5972 | 49 | II | + | + | α, β, δ | 0 | ++ |
| IMT31819* | 130 | III | − | − | None | 0 | 0 |
| IMT32510 | 130 | III | + | Weak + | Weak β | 0 | ++ |
| IMT32929 | 130 | III | + | Weak + | β | 1 | ++ |
| IMT34478 | 130 | III | + | − | None | 1 | 0 |
| IMT34479 | 130 | III | + | + | β, δ | 1 | ++ |
| IMT34480 | 130 | III | + | + | β, δ | 1 | ++ |
| IMT34488 | 130 | III | + | + | α, β, δ | 0 | ++ |
| IMT34489 | 130 | III | − | − | None | 0 | 0 |
| IMT34491 | 130 | III | + | + | α, β, δ | 0 | ++ |
| IMT36946 | 130 | III | + | + | α, β, δ | 0 | ++ |
| IMT36950 | 130 | III | + | + | α, β, δ | 0 | ++ |
| IMT38115 | 130 | III | + | + | α, β, δ | 0 | ++ |
| IMT38119* | 130 | III | + | + | α, β, δ | 0 | ++ |
| IMT39816 | 130 | III | + | + | α, β, δ | 0 | ++ |
| IMT39819 | 130 | III | + | + | α, β, δ | 2 | ++ |
| IMT40506 | 130 | III | + | + | α, β, δ | 1 | ++ |
| IMT41554 | 130 | III | + | + | α, β, δ | 1 | ++ |
| RKI5965 | 130 | III | Weak + | + | α, β, δ | 1 | ++ |
| RKI5966* | 130 | III | − | + | β | 0 | 0 |
| RKI5967 | 130 | III | + | + | α, β, δ | 0 | ++ |
| RKI5968 | 130 | III | + | + | α, β, δ | 1 | ++ |
| IMT34485 | 1943 | IV | + | + | α, β, δ | 0 | ++ |
| IMT36952 | 1943 | IV | − | − | None | 2 | 0 |
| IMT38113 | 1943 | IV | + | − | α, δ | 0 | ++ |
| IMT39820 | 1943 | IV | + | + | α, β, δ | 0 | ++ |
| IMT40504 | 1943 | IV | + | + | α, β, δ | 0 | ++ |
| IMT40507 | 1943 | IV | + | − | α, δ | 0 | ++ |
| RKI5969 | 1943 | IV | + | + | α, β, δ | 0 | ++ |
| RKI5970 | 1943 | IV | + | + | α, β, δ | 0 | ++ |
| RKI5971 | 1943 | IV | + | + | α, β, δ | 0 | ++ |
| RKI5973 | 1943 | IV | Weak + | − | α, δ | 2 | ++ |
Genomic variation within the agr encoding region is indicated by use of bold ID letters (for details see Fig. 2). The isolates further investigated with respect to biofilm structures using CLSM are marked with *. Agr activity prediction according to Hld values presented in Fig. 4a (0, +, ++).
ID, isolate number; CC, clonal complex; agr, accessory gene regulatory type; CS, colony spreading (phenotypical verification for agr functionality); CAMP, phenotypical verification for β-haemolysin production; SPDH, test results for synergistic production of different heamolysins using RN4220 (phenotypical verification of α-, β- and δ-haemolysin production); BF, biofilm formation (mean absorbance 492 nm; values: 0, < 0.2811; 1, 0.2811 < x < 1.0; 2, > 1.0); + , positive; −, negative.